Saxenda is a registered trademark of Novo Nordisk A/S
doi: 10.3389/fnagi.2025.1626417, 45 VenkateshappaC.HarishG.MahadevanA.Srinivas BharathM
2015;385 Suppl 1:S68
We further detected the protein level of SREBF1 and PLIN2 in GSTM2 knockdown cells treated with PA or GS-4997
Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
2 m The UACR was calculated with albumin measured in milligrams and creatinine measured in grams